According to a new trial, researchers showed the clinical practice guideline which includes major sanctions for the use of blood thinning medication (anticoagulants) during heart surgery. The guideline was published in The Annals of Thoracic Surgery and in two other journals.
Linda Shore-Lesserson said, "It is our hope that these guidelines will help clinicians practice consistent and safe anticoagulation and that there will be more standardization in practice."
Cardiopulmonary Bypass and the Role of Anticoagulation
Anticoagulation therapy is critically important during cardiopulmonary bypass (CPB), a technique that temporarily takes over the function of the heart and lungs during heart surgery. The blood is removed from the body, sent through the CPB pump and then returned to the body, bypassing the normal pathway of blood through the heart and lungs.
Exposing the blood to the artificial surfaces of the heart-lung machine and its components, however, predisposes the blood to clotting. As a result, the clotting ability of the blood must be inhibited by blood thinning drugs (such as heparin) and reversed at the end of the procedure with agents such as protamine-;a strategy that allows heart surgery to be conducted safely and successfully.
"Until now, there has been no standardization of this important practice or the use of these anticoagulant drugs," said Dr. Shore-Lesserson. "These recommendations will help fill the evidence gap and establish best practices in anticoagulation therapy for cardiopulmonary bypass."
STS believes that the practice of summarizing current scientific evidence into clinical practice guidelines and recommendations may contribute importantly to improving surgical outcomes, as well as the quality of patient care. In this case, to identify relevant evidence, a systematic review was outlined and extensive literature searches were conducted by a workgroup.
The new clinical practice guideline offers evidence-based recommendations that include:
- Optimal heparin dosing for initiation and maintenance of cardiopulmonary bypass;
- Identification of contraindications to the use of heparin;
- Options for alternatives to heparin; and
- Ideal methods for reversal of anticoagulation after CPB.
Dr. Shore-Lesserson said that even with these new guidelines, "more and better evidence" needs to be generated to answer many questions that clinicians still may have, especially in the area of alternative drugs to heparin. According to Dr. Shore-Lesserson, heparin and protamine have been cardiac surgery staples for more than 50 years and remain the gold standard, but "they are not perfect."
So a call to action is now in place for investigators to conduct important prospective scientific trials and meta-analyses so that new knowledge is generated. Dr. Shore-Lesserson said, they ?hope that this guideline will stimulate representatives to conduct more research and to expand on the evidence base regarding anticoagulation therapy for cardiopulmonary bypass.